Atrial fibrillation after coronary artery bypass surgery: Possibilities of prevention
| Autor: | Milos Velinovic, Natasa Kovacevic-Kostic, Mile Vranes, Bojana Orbovic, Stana Ristic, Biljana Obrenovic-Kircanski, Biljana Parapid |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Digoxin Adrenergic beta-Antagonists lcsh:Medicine Amiodarone Coronary artery bypass surgery Internal medicine postoperative atrial fibrillation Atrial Fibrillation Humans Medicine Myocardial infarction cardiovascular diseases Coronary Artery Bypass Stroke amiodarone business.industry Sotalol lcsh:R Atrial fibrillation General Medicine medicine.disease myocardial revascularization Anesthesia Heart failure Cardiology cardiovascular system business Anti-Arrhythmia Agents medicine.drug |
| Zdroj: | Srpski Arhiv za Celokupno Lekarstvo, Vol 140, Iss 7-8, Pp 521-527 (2012) |
| ISSN: | 0370-8179 |
| Popis: | Atrial fibrillation occurs as a frequent complication after cardiac interventions. It can be found in 5% of all surgical patients, and it is far more common in cardiac (10% - 65% of patients) than in non-cardiac procedures. In a number of patients it remains asymptomatic, but may be accompanied by very severe symptoms of hypotension, heart failure, syncope, systemic or pulmonary embolism, perioperative myocardial infarction, cerebrovascular insult and increased operative mortality. Patients whose postoperative course is complicated by atrial fibrillation require longer hospitalization. Possible predisposing factors of this arrhythmia are numerous and are associated with surgery, extensive coronary heart disease and revascularization, and preoperative diseases. According to the recommendations of the European Society of Cardiology orally applied beta-blocker, amiodarone and sotalol can be used for prophylaxis of atrial fibrillation. Following the recommendations, treatment of postoperative atrial fibrillation should include beta-blockers, amiodarone, and in patients with heart failure and left ventricular dysfunction, digoxin. Due to the increased risk of stroke, an anticoagulant protection is necessary. Many studies have been conducted with results supporting the prophylactic use of amiodarone and beta-blockers, while the treatment with new agents such as magnesium, statins, omega-3 fatty acids and inhibitors of the renin-angiotensin-aldosterone system is still being investigated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|